Long trade : Eleven Biotherapeutics (EBIO) +50% (9/17)

a.  8/24:  $1.05   vol. 212K   →  +50%
b.  9/7  ;  $1.15  vol. 116K  →  +40%

  

weekly

monthly

Eleven Biotherapeutics (EBIO) reported earnings on Mon 14 November 2016 (b/o)

** charts after earnings **

 

• The day after:

Eleven Biotherapeutics reports Q3 results :

• Net income was $19.5 million, or $0.95 per basic share and $0.91 per diluted share, for the three months ended September 30, 2016, compared to a net loss of $9.7 million, or $0.50 per basic and diluted share, for the same period in 2015 (no estimates).
• Revenue was $28.7 million for the three months ended September 30, 2016, compared to $0.1 million for the same period in 2015. The increase was due to the revenue recognized from the License Agreement with Roche.
• "We anticipate complete enrollment in the first half of next year for our Phase 3 clinical trial of Vicinium as a potential treatment for high-grade non-muscle invasive bladder cancer, and expect topline data in the first half of 2018," said Stephen Hurly, President and Chief Executive Officer of Eleven Biotherapeutics. "We also plan to initiate our Phase 2 trial in late-stage squamous cell carcinoma of the head and neck with Proxinium in combination with a checkpoint inhibitor in the first half of 2017. Also in 2017, we plan on submitting an IND with the FDA for our lead product in our systemic pipeline based on our proprietary payload deBouganin. With the combined expertise of Eleven and the Viventia team, I am very excited about the opportunities we have ahead."